Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OD-PHOENIX
- Development stage
- Preclinical
- Lead developer
- TBF Génie Tissulaire
- Modality
- Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies, Other Cell Types → Cell Therapies
- Administration
- Surgical Implantation
01
Overview
OD-PHOENIX is a decellularized, freeze-dried, irradiated osteochondral allograft developed by TBF Genie Tissulaire. It is designed to treat osteochondral lesions in joints, such as the talus and knee, by providing a processed allogeneic osteochondral material for implantation. This approach aims to avoid the need for autograft material harvesting from the patient's own body.
Beyond the preview
Go deeper on OD-PHOENIX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OD-PHOENIX.